I 2 placebo- kontrollerede, randomiserede, dobbeltblinde undersøgelser havde de patienter, der var i behandling med NEVANAC, væsentligt mindre inflammation (celler og flare i kammervæske) fra den tidlige postoperative periode til endt behandling end de patienter, der blev behandlet med placebo.
Additionally, nearly all patients received prophylactic treatment with antibiotics, according to clinical practice at each of the clinical trial sites 5 In two double-masked, randomised placebo-controlled studies, patients treated with NEVANAC had significantly less inflammation (aqueous cells and flare) from the early postoperative period through the end of treatment than those treated with placebo.